TORONTO and HAIFA, Israel, March 14, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that it has successfully completed an important preclinical study towards its Investigational New Drug (“IND”) submission. The new study, which advances the Company’s path towards first-in-human trials, demonstrated that ExoPTEN treatment with different dose regimens led to both motor function recovery and significant improvements in blood flow at the site of spinal cord injury—an essential factor in tissue healing and functional recovery.i
“This preclinical study evaluated dosing regimens to provide efficacy data in support of our IND submission,” said Dr. Tali Kizhner, Director of R&D at NurExone. “The results reinforce ExoPTEN’s potential to enhance the body’s natural repair mechanisms following spinal cord injury. Notably, the increased blood vessel size observed in treated subjects indicated improved circulation, which is crucial for oxygen and nutrient delivery to damaged tissues. These findings suggest that ExoPTEN has the potential to become a transformative therapeutic candidate, and we are eager to advance toward clinical trials.”